Print Page Close Window|
Investors and Media
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases.
Recent NewsApr 18, 2017Idera Pharmaceuticals Announces Organizational UpdateRead MoreApr 11, 2017Idera Pharmaceuticals Advances Investigational Treatment – Intratumoral IMO-2125 in Combination with Ipilimumab - for Unmet Need in Anti-PD-1 Refractory Metastatic MelanomaRead MoreApr 05, 2017Idera Pharmaceuticals Presents Clinical Translational and Pre-Clinical Data from IMO-2125 Development Program at the American Association for Cancer Research (AACR) 2017 Annual MeetingRead More
|There are currently no events scheduled.|
|There are currently no items available.|
Data provided by Nasdaq. Minimum 15 minutes delayed.